Kallyope is a biotechnology firm committed to deciphering the therapeutic potential of the gut-brain axis. The company's multidisciplinary team merges sophisticated technologies such as sequencing, bioinformatics, neural imaging, cellular and molecular biology, and human genetics. This integration offers users an in-depth knowledge of gut-brain biology that paves the way for revolutionary therapeutics aimed at enhancing human health.

Investors Include:

William Gates, Bill Gates, Lux Capital, Euclidean Capital, Illumina Ventures, Mubadala Investment Company, The Column Group, Hartford Healthcare Endowment, Two Sigma Ventures, Illumina, Anthony Evnin, Columbia Technology Ventures, DNS Capital, Casdin Capital, Polaris Partners, Alexandria Venture Investments, StepStone Group, Tao Capital Partners.

Looking to sell Kallyope Stock or Options?

We have an even better solution: The Collective Exchange Fund

Get in touch and see if we can help you